Introduction
An orphan drug is a medicine for a rare disease, which US law defines as one affecting fewer than 200,000 Americans. The Orphan Drug Act of 1983 turned those small markets into one of the most attractive sub-segments in healthcare for investors, acquirers and bankers. A higher probability of success, premium pricing, a dedicated exclusivity period and a carve-out from IRA price negotiation create a favorable economic profile that commands premium valuations.
The Structural Advantages
Higher Clinical Success Rates
In the BIO, Informa and QLS study of 2011-2020 clinical development, non-oncology rare disease programs had a likelihood of approval from Phase I of 17.0%, slightly over double the 7.9% average across all indications and almost three times the 5.9% for chronic, high-prevalence diseases. The widest gap opens in Phase II, where 44.6% of rare disease programs advanced against 28.9% overall.
The edge has narrowed: BIO's previous study (2006-2015 data) put the rare disease figure at 25.3%, and the authors link the fall to sponsors moving into conditions whose biology is poorly understood. The remaining advantage comes from clear genetic drivers that enable precise patient selection, focused trial designs and the FDA's flexibility on surrogate endpoints and single-arm trials.
Premium Pricing
Smaller, Faster, Cheaper Trials
Rare disease trials enroll fewer patients (often 50-200 for a pivotal trial vs. 1,000-5,000 for mass-market drugs), are often single-arm (no placebo comparator), and can use surrogate endpoints for accelerated or traditional approval. This can bring development costs down to roughly $20-100 million (vs. $200-500 million for a full mass-market development program) and compresses timelines.
Regulatory Protection: Orphan Exclusivity and the IRA
Seven-Year Exclusivity
The Orphan Drug Act grants 7 years of market exclusivity once a designated drug is approved for its rare indication. Because this is regulatory exclusivity rather than a patent, it runs independently of the patent estate and cannot be invalidated in litigation.
- Orphan Drug Designation
FDA status granted under the Orphan Drug Act to a drug for a disease affecting fewer than 200,000 people in the US (or more, where US sales cannot be expected to recover development costs). It unlocks a clinical trial tax credit, an FDA user fee exemption and, on approval for the designated use, 7 years of orphan exclusivity.
The moat is narrower than it sounds. It blocks only the same drug for the same indication, so a different molecule for the same disease can still be approved. It also matters most for small molecules: 7 years beats the 5-year new chemical entity exclusivity, but biologics already receive 12 years of reference product exclusivity.
The IRA Orphan Drug Exclusion
The original IRA excluded from Medicare price negotiation only drugs designated for a single rare disease and approved solely for it. The One Big Beautiful Bill Act, signed in July 2025, widened the exclusion to drugs designated for one or more rare diseases and approved only for those uses. As Sidley's summary of the amendment explains, a drug that later wins a non-orphan indication now starts its negotiation clock at that first non-orphan approval rather than at launch. A rare disease franchise can therefore add rare indications without losing the exclusion.
Rare Disease M&A Activity
These economics have produced some of the largest deals in healthcare, as buyers pay for durable pricing, protected exclusivity and a commercial model where a small specialist sales force covers the treating physicians.
| Acquirer-Target | Closed | Value | Target Disease Area |
|---|---|---|---|
| Sanofi-Genzyme | 2011 | $20B | Lysosomal storage disorders |
| Takeda-Shire | 2019 | $62B | Rare disease portfolio |
| AstraZeneca-Alexion | 2021 | $39B | Rare hematology, complement |
| Amgen-Horizon Therapeutics | 2023 | $28B | Rare autoimmune/inflammatory |
| Novartis-Avidity Biosciences | 2026 | $12B | Genetic neuromuscular diseases |
Earlier deals bought commercial franchises, such as Alexion's complement inhibitors (Soliris and Ultomiris) or Horizon's Tepezza and Krystexxa. Buyers now also pay for pipeline: Novartis completed its roughly $12 billion acquisition of Avidity Biosciences in February 2026 for late-stage genetic neuromuscular programs with no marketed product. In biotech M&A, such targets are priced on probability-weighted pipeline value, so higher success rates feed directly into the bid.
This article concludes the Biotech section. The next section covers Medical Devices & MedTech, where the business model, regulatory pathways, and valuation drivers are fundamentally different from both pharma and biotech.
